These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 30555735)
21. Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women. Sapino A; Righi L; Cassoni P; Papotti M; Gugliotta P; Bussolati G Mod Pathol; 2001 Aug; 14(8):768-76. PubMed ID: 11504836 [TBL] [Abstract][Full Text] [Related]
22. The potential role for prolactin-inducible protein (PIP) as a marker of human breast cancer micrometastasis. Clark JW; Snell L; Shiu RP; Orr FW; Maitre N; Vary CP; Cole DJ; Watson PH Br J Cancer; 1999 Nov; 81(6):1002-8. PubMed ID: 10576657 [TBL] [Abstract][Full Text] [Related]
23. Differential antibody reactivity and CD4 binding of the mammary tumor marker protein GCDFP-15 from breast cyst and its counterparts from exocrine epithelia. Caputo E; Autiero M; Mani JC; Basmaciogullari S; Piatier-Tonneau D; Guardiola J Int J Cancer; 1998 Sep; 78(1):76-85. PubMed ID: 9724097 [TBL] [Abstract][Full Text] [Related]
24. Structural study of GCDFP-15/gp17 in disease versus physiological conditions using a proteomic approach. Caputo E; Camarca A; Moharram R; Tornatore P; Thatcher B; Guardiola J; Martin BM Biochemistry; 2003 May; 42(20):6169-78. PubMed ID: 12755619 [TBL] [Abstract][Full Text] [Related]
26. The human breast cancer-associated protein, the prolactin-inducible protein (PIP), regulates intracellular signaling events and cytokine production by macrophages. Ihedioha O; Blanchard AA; Balhara J; Okwor I; Jia P; Uzonna J; Myal Y Immunol Res; 2018 Apr; 66(2):245-254. PubMed ID: 29536339 [TBL] [Abstract][Full Text] [Related]
27. Unusual N-type glycosylation of salivary prolactin-inducible protein (PIP): multiple Lewis Wiegandt A; Behnken HN; Meyer B Glycoconj J; 2018 Jun; 35(3):323-332. PubMed ID: 29858715 [TBL] [Abstract][Full Text] [Related]
28. Prolactin inducible protein in cancer, fertility and immunoregulation: structure, function and its clinical implications. Hassan MI; Waheed A; Yadav S; Singh TP; Ahmad F Cell Mol Life Sci; 2009 Feb; 66(3):447-59. PubMed ID: 18854942 [TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical localization of gross cystic disease fluid protein-15, -24 and -44 in ductal carcinoma in situ of the breast: relationship to the degree of differentiation. Selim AA; El-Ayat G; Wells CA Histopathology; 2001 Aug; 39(2):198-202. PubMed ID: 11493337 [TBL] [Abstract][Full Text] [Related]
30. Prolactin-Induced Protein regulates cell adhesion in breast cancer. Vanneste M; Naderi A Biochem Biophys Res Commun; 2015 Dec; 468(4):850-6. PubMed ID: 26585492 [TBL] [Abstract][Full Text] [Related]
31. Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1 activity. Sriram R; Lo V; Pryce B; Antonova L; Mears AJ; Daneshmand M; McKay B; Conway SJ; Muller WJ; Sabourin LA Breast Cancer Res; 2015 Jan; 17(1):7. PubMed ID: 25592291 [TBL] [Abstract][Full Text] [Related]
32. Expression of the gene encoding a prolactin-inducible protein by human breast cancers in vivo: correlation with steroid receptor status. Murphy LC; Lee-Wing M; Goldenberg GJ; Shiu RP Cancer Res; 1987 Aug; 47(15):4160-4. PubMed ID: 3607757 [TBL] [Abstract][Full Text] [Related]
33. Immunohistochemistry of GCDFP-24 and zinc alpha2 glycoprotein in benign sweat gland tumors. Mazoujian G Am J Dermatopathol; 1990 Oct; 12(5):452-7. PubMed ID: 2244662 [TBL] [Abstract][Full Text] [Related]
34. Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast. Lininger RA; Zhuang Z; Man Y; Park WS; Emmert-Buck M; Tavassoli FA Mod Pathol; 1999 Dec; 12(12):1083-9. PubMed ID: 10619258 [TBL] [Abstract][Full Text] [Related]
35. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. Honma N; Takubo K; Akiyama F; Sawabe M; Arai T; Younes M; Kasumi F; Sakamoto G Histopathology; 2005 Aug; 47(2):195-201. PubMed ID: 16045781 [TBL] [Abstract][Full Text] [Related]
36. Prolactin-induced protein as a potential therapy response marker of adjuvant chemotherapy in breast cancer patients. Jablonska K; Grzegrzolka J; Podhorska-Okolow M; Stasiolek M; Pula B; Olbromski M; Gomulkiewicz A; Piotrowska A; Rys J; Ambicka A; Ong SH; Zabel M; Dziegiel P Am J Cancer Res; 2016; 6(5):878-93. PubMed ID: 27293986 [TBL] [Abstract][Full Text] [Related]
37. Comparative study of monoclonal antibody B72.3 and gross cystic disease fluid protein-15 as markers of apocrine carcinoma of the breast. Honma N; Takubo K; Arai T; Younes M; Kasumi F; Akiyama F; Sakamoto G APMIS; 2006 Oct; 114(10):712-9. PubMed ID: 17004974 [TBL] [Abstract][Full Text] [Related]
38. Identity of human extra parotid glycoprotein (EP-GP) with secretory actin binding protein (SABP) and its biological properties. Schenkels LC; Schaller J; Walgreen-Weterings E; Schadee-Eestermans IL; Veerman EC; Nieuw Amerongen AV Biol Chem Hoppe Seyler; 1994 Sep; 375(9):609-15. PubMed ID: 7840903 [TBL] [Abstract][Full Text] [Related]
39. Human seminal plasma prolactin-inducible protein is an immunoglobulin G-binding protein. Chiu WW; Chamley LW J Reprod Immunol; 2003 Dec; 60(2):97-111. PubMed ID: 14638438 [TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical analysis of GCDFP-15 and GCDFP-24 in mammary and non-mammary tissue. Satoh F; Umemura S; Osamura RY Breast Cancer; 2000 Jan; 7(1):49-55. PubMed ID: 11029771 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]